Cargando…

The change of drug utilization in China’s public healthcare institutions under the “4 + 7” centralized drug procurement policy: Evidence from a natural experiment in China

Background: Improving drug accessibility and rational drug use are major challenges for China’s healthcare reform. In 2018, the Chinese government introduced a novel nationwide policy of centralized drug procurement for off-patent drugs, focusing on improving drug utilization patterns of public medi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Jiancheng, Long, Hongfei, Shen, Yuan, Wang, Jing, Geng, Xin, Yang, Ying, Mao, Zongfu, Li, Jinghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445493/ https://www.ncbi.nlm.nih.gov/pubmed/36081942 http://dx.doi.org/10.3389/fphar.2022.923209

Ejemplares similares

Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series
por: Long, Hongfei, et al.
Publicado: (2022)

The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
por: Chen, Lei, et al.
Publicado: (2020)

Antibiotic Use in China’s Public Healthcare Institutions During the COVID-19 Pandemic: An Analysis of Nationwide Procurement Data, 2018–2020
por: Yang, Ying, et al.
Publicado: (2022)

Healthcare professionals’ knowledge, attitude and practice towards National Centralized Drug Procurement policy in central China: A cross-sectional study
por: Huang, Anqi, et al.
Publicado: (2022)

The impact of key monitoring policy on the usage of policy-related drugs in Hubei Province, China
por: Wen, Xiaotong, et al.
Publicado: (2023)

Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China
por: Zhao, Xinyu, et al.
Publicado: (2022)

Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement
por: Zhang, Wen, et al.
Publicado: (2023)

Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
por: Wang, Ni, et al.
Publicado: (2021)

Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls
por: Chen, Yilin, et al.
Publicado: (2021)

Impact of ‘4+7’ volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China
por: Wang, Jing, et al.
Publicado: (2022)

A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China
por: Wen, Xiaotong, et al.
Publicado: (2023)

Does China’s centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model
por: Gu, Yang, et al.
Publicado: (2023)

The Effects of a New Public Medicine Procurement Policy on Medicine Price in Shaanxi Province, Western China: An Interrupted Time Series Analysis
por: Hu, Shuchen, et al.
Publicado: (2019)

The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis
por: Yang, Ying, et al.
Publicado: (2021)

The impact of “4 + 7” volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis
por: Yang, Ying, et al.
Publicado: (2021)

Antibiotic Expenditure by Public Healthcare Institutions in Shandong Province in China, 2012–2016
por: Yin, Jia, et al.
Publicado: (2018)

National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018
por: Shi, Honghao, et al.
Publicado: (2021)

Impact of China’s National Centralized Drug Procurement Policy on pharmaceutical enterprises’ financial performance: a quasi-natural experimental study
por: Sun, Zhixuan, et al.
Publicado: (2023)

Does China improve social welfare after implementing the national volume-based procurement?
por: Wang, Huan, et al.
Publicado: (2023)

Distribution of essential medicines to primary care institutions in Hubei of China: effects of centralized procurement arrangements
por: Yang, Lianping, et al.
Publicado: (2017)

Drug procurement, the Global Fund and misguided competition policies
por: Tren, Richard, et al.
Publicado: (2009)

China’s drug clinical trial institution record-keeping system: Qualification requirements for PI are the key
por: Huang, Nanqu, et al.
Publicado: (2023)

Analysis of drug resistance in pulmonary tuberculosis patients with positive sputum tuberculosis culture in Northeast China
por: Sichen, Li, et al.
Publicado: (2023)

Government Policy for the Procurement of Food from Local Family Farming in Brazilian Public Institutions
por: Soares, Panmela, et al.
Publicado: (2021)

Can the Profitability of Medical Enterprises Be Improved After Joining China's Centralized Drug Procurement? A Difference-in-Difference Design
por: Hua, Yu-Fei, et al.
Publicado: (2022)

Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus
por: Yuan, Jing, et al.
Publicado: (2022)

Reevaluation of adverse drug reactions of psychiatric drugs under the chinese drug volume-based procurement policy
por: Du, Zhiqiang, et al.
Publicado: (2022)

Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies
por: Garattini, Silvio, et al.
Publicado: (2021)

Improving access to medicines and beyond: the national volume-based procurement policy in China
por: Zhu, Zheng, et al.
Publicado: (2023)

Drug and therapeutics committee interventions in managing irrational drug use and antimicrobial stewardship in China
por: Yang, Jing, et al.
Publicado: (2022)

Therapeutic Drug Monitoring and Pharmacogenetic Testing in Northern China
por: Zhang, Chunyan, et al.
Publicado: (2021)

Analysis of Suspension of Clinical Trials for Drug Registration in China
por: Su, Xian, et al.
Publicado: (2021)

The Characteristics, Prevalence, and Risk Factors of Drug-Induced Liver Injury Among Brucellosis Inpatients in Xinjiang, China
por: Tuohutaerbieke, Maermaer, et al.
Publicado: (2021)

The impacts of the “4+7” pilot policy on the volume, expenditures, and daily cost of Serotonin-Specific Reuptake Inhibitors (SSRIs) antidepressants: A quasi-experimental study
por: Wen, Xiaotong, et al.
Publicado: (2022)

Seven-year exclusivity and beyond for drugs of rare diseases in China
por: Jiang, Yale, et al.
Publicado: (2023)

Procurement of Category 2 Vaccines in China
por: Zhuang, Jian-Lin, et al.
Publicado: (2019)

Analysis of Antibiotic Use Patterns and Trends Based on Procurement Data of Healthcare Institutions in Shaanxi Province, Western China, 2015–2018
por: Xu, Sen, et al.
Publicado: (2020)

Sustainable public procurement in a Brazilian higher education institution
por: Mendonça, Renata C. A., et al.
Publicado: (2021)

Knowledge, Attitude and Practice of Hospital Pharmacists in Central China Towards Adverse Drug Reaction Reporting: A Multicenter Cross‐Sectional Study
por: Hu, Wen, et al.
Publicado: (2022)

Creating China’s Biosimilar Drugs Regulatory System: A Calculated Approach
por: Yang, Jianhong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_11bj8un0c4n1sajtu8q3vqbme6